Arcalyst rilonacept regulatory update

Regeneron said that in July it submitted an MAA to EMEA for Arcalyst to treat cryopyrin-associated periodic syndrome (CAPS), a family of rare autoinflammatory diseases caused by mutations in the CIAS1...